TMCnet News
Axim® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing CannabinoidsNEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) on a method to treat atopic dermatitis, also known as eczema, using a topical cream containing cannabinoids – specifically cannabidiol (“CBD”) and cannabigerol (“CBG”). The USPTO granted this allowance from AXIM’s patent application 16/106,524, filed on August 21, 2018. With this patent allowance, AXIM has formulated a topical cream for relief of itching, pain and inflammation that often accompany atopic dermatitis. All creams formulated under this patent will contain cannabinoids and utilize AXIM’s proprietary combination of CBG and CBD. AXIM’s topical cream is projected to be one of the first CBG products available on the market. “As AXIM moves forward with its long-term business strategy, this patent allowance offers the opportunity to bring another one of our innovative products into the pipeline for both pharmaceutical and nutraceutical markets,” said John W. Huemoeller, CEO of AXIM Biotech. “This patent allowance expands our intellectual property portfolio and makes room for us to build treatment options for consumers suffering from varying medical conditions. Through the formulaion of one of the first CBG products available to consumers, AXIM remains a leader in cannabinoid research and development.” This patent allowance also grants protection for a method to treat atopic dermatitis using a cannabinoid topical cream like above and chewing gums containing cannabinoids, another product protected by a patent in AXIM’s current patent portfolio. The combination of AXIM’s various patented products and methods works to accentuate the value of AXIM’s intellectual property portfolio and exemplifies AXIM’s research and development direction. Research has shown evidence that both CBD and CBG provide anti-inflammatory and pain relief benefits. AXIM’s proprietary blend of CBG and CBD is the ideal combination for harnessing these benefits. AXIM aims to provide consumers with a topical cream for the $5 billion atopic dermatitis treatment market. To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/. About AXIM® Biotechnologies AXIM's flagship products include MedChew® with Dronabinol, which is planned to undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; Medchew RLTM, which is planned to undergo clinical trials for treatment of restless leg syndrome; and MedChew RxTM, a combination cannabidiol (CBD)/tetrahydrocannabinol (THC) functional, controlled-release chewing gum that is planned to undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS). For more information, please visit www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER LEGAL DISCLOSURE Public Relations Contact: Corporate Contact Info: European Address:
|